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The Revised Report of Verified Case of Tuberculosis
What is the Report of Verified Case of
Tuberculosis?
What is the significance of surveillance?
The Report of Verified Case of Tuberculosis (RVCT) is
the national TB surveillance form.  Data are collected
by state and local TB programs and submitted
electronically to the Centers for Disease Control and
Prevention (CDC), Division of Tuberculosis Elimination
(DTBE).  These data are used to monitor national TB
trends, identify priority needs, and create the DTBE
Annual Surveillance Report.
Surveillance is essential to successful TB control. It is a
key component of program evaluation and provides a
measurement of progress toward TB elimination.  State
and local surveillance data are essential in providing the
epidemiologic profile of TB in a given jurisdiction, as
well as on a national level. For example, surveillance
data from local and state TB control programs were
used to identify the reversal of the declining trend in TB
incidence in the United States in the mid-1980’s, the
peak of resurgence in 1992, and the subsequent steady
decline to an unprecedented low number and rate of TB
cases in 2007.
Why is the RVCT changing?
To control and eventually eliminate TB, state and local
TB control programs must be able to monitor trends in
TB disease in high risk populations, as well as identify
new patterns of disease and possible outbreaks.  The
last major revision of the RVCT was completed in
1993—over 15 years ago!  Modification of the RVCT
is needed to accommodate the changing epidemiology
of TB in terms of risk factors, new drug treatments,
enhanced laboratory capacity for diagnostic tests, and
to identify priority needs.
Timely and accurate reporting of suspected and
confirmed TB cases, with inclusion of useful case data,
is necessary for public health planning and assessment
at all levels.  The new data elements included in the
revised RVCT will assist in this process.
Who worked on the revision?
Beginning in 2001, a DTBE-sponsored work group
consisting of nearly 30 members from 15 TB control
programs, DTBE, and the National TB Controllers
Association (NTCA) worked to draft the revised
RVCT. The work group made variable additions,
deletions, and modifications that will improve data
collection, yield meaningful and useful data, and be
significant for surveillance.
What are the enhancements to the RVCT?
The revised RVCT includes risk factors such as
diabetes, end-stage renal disease, immunosuppressive
therapy, and contact with a drug-resistant case. It
enables collection of data on parental origin for
pediatric TB patients, primary reason for evaluation of
TB disease, whether the patient moved, immigration
status, the reason therapy was extended, drug
susceptibility testing (newer drugs for susceptibility
testing), and outcome of directly observed therapy
(DOT). Enhancements accommodate the multiple
changes in technology that have occurred in recent
years, such as nucleic acid amplification tests, interferon
gamma release assays, computerized tomography, and
genotyping. The changes also capture data on TB cases
not meeting the current surveillance definition. The
RVCT case number was modified to include the year
and jurisdictional code.  This allows each TB case to be
allocated a unique number with a “linking state case
number” field to record source cases or prior TB
episodes.
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The revised RVCT will assist TB control programs in
gathering accurate, useful data. The additions and
changes made to the variables of the RVCT will enable
programs to capture data that are more inclusive of a
variety of risk factors.  These additional data will be
essential to efficient and effective TB program
management.
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implemented?
How will the changes affect TB control
programs?
The revised RVCT was field tested by TB program
staff. After OMB approves the revised RVCT,
implementation of the new form will begin on January
2009. The final form, instructions, and Self-Study
Modules will be available in the fall of 2008.
How can health professionals learn how to
accurately complete the revised RVCT?
The Report of Verified Case of Tuberculosis (RVCT)
Self-Study Orientation Modules include instructions,
examples, and exercises to help health professionals
learn how to accurately complete the RVCT.  In
addition, the modules can be used in facilitator-led
orientation sessions.
Note: A verified case of TB for public health surveillance may be laboratory confirmed or, in the absence of
laboratory confirmation, meet the clinical case definition as defined in the CDC document “Case Definitions for
Infectious Conditions Under Public Health Surveillance.” The criteria for determining a laboratory confirmed case
are
1) isolation of M. tuberculosis complex from a clinical specimen;
2) demonstration of M. tuberculosis from a clinical specimen by nucleic acid amplification test; or
3) demonstration of acid-fast bacilli in a clinical specimen when a culture has not been or cannot be obtained.
A clinically verified case of TB meets all of the following criteria:
1) a positive tuberculin skin test;
2) signs and symptoms compatible with current TB disease, such as an abnormal, unstable (worsening or
improving) chest x-ray, or clinical evidence of current disease;
3) current treatment with two or more antituberculosis medications; and
4) a completed diagnostic evaluation.
